At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 173 enrolled

Drug / intervention

Daclatasvir +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02032901

NCT02032901Phase 3Completed

A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection

Bristol-Myers Squibb·interventional·Posted Jan 10, 2014·Updated Oct 1, 2015

In Brief

A Phase 3 clinical trial evaluating Daclatasvir and Sofosbuvir for Hepatitis C. Completed, enrolled 173 participants across 31 sites in 2 countries.

To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesPuerto Rico, United States

Collaborators--

Phase 3CompletedFinished

2014201520162017201820192020202120222023202420252026

Enrollment StartJan 2014

First PostedJan 2014

Primary CompletionSep 2014

Study CompletionDec 2014

TodayJul 2026

First PostedJan 10, 2014

Enrollment StartJan 1, 2014

Primary CompletionSep 1, 2014

Study CompletionDec 1, 2014

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 12.5 years ago

Daclatasvirdrug

Sofosbuvirdrug